METformin And Longevity (METAL): A window of opportunity study investigating biological effects of metformin in localised prostate cancer - META

King's College London0 个研究点开始时间: 2015年2月9日最近更新: 2017年1月31日

适应症

试验速览

暂无简介。

•1. Age 18 or older and willing and able to provide signed informed consent.
•2. Histologically confirmed adenocarcinoma of the prostate , with a maximal tumour length of greater or equal to 6mm on core biopsy
•3. No previous treatment for prostate cancer (including surgery, any hormone therapy, radiotherapy and cryotherapy)
•4. Prostate biopsy within 6 months from screening.
•5. Radical prostatectomy is the scheduled treatment of choice
•6. Eastern Cooperative Oncology Group (ECOG) Performance status less than or equal to 0 or 1.
•7. Adequate organ function, defined as follows:
•Haemoglobin >10.0g/dL
•Absolute neutrophil count >1.5x109/L
•Platelet count >100x109/L
•Renal function, eGFR >60ml/min (calculated by Cockcroft Gault)
•AST and/or ALT <2.5 x ULN
•Total Bilirubin <1.5 x ULN
•8. Able to swallow the drug and comply with study requirements.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 15
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 90

•1. Patients with a current or historical diagnosis of type one or two Diabetes and/or have ever received metformin
•2. Patients with hypersensitivity to any of the components of Metformin or placebo tablet
•3. History of or conditions associated with lactic acidosis such as shock or pulmonary insufficiency, alcoholism (acute or chronic), and conditions associated with hypoxaemia
•4. Patients with chronic liver disease, severe cardiovascular impairment, cardiac failure, recent myocardial infarction, severe peripheral vascular disease or renal impairment (eGFR <60ml/min as measured by Cockcroft Gault)
•5. Patients with acute severe disorders, for example infections with fever, pancreatitis, trauma, dehydration or reduced diet (<1000kcal or 4200kJ per day)
•6. Other active malignancy over the last five years that has required systemic therapy, excluding:
•a. Adjuvant therapy in the curative setting
•b. Non-melanoma skin cancer
•c. Superficial transitional cell carcinoma (CIS-T1)
•7. Current enrolment in an investigational drug or device study or participation in such a study within 30 days of signing consent.
•8. Any subjects who is able to father a child and does not agree to use barrier protection, in the form of a condom ,for the duration of the trial and for 16 weeks after the last study drug administration.

发起方